Pharmaceutical Flow Cytometry & Imaging
The 5th biennial Pharmaceutical Flow Cytometry and Imaging meeting will be held at GlaxoSmithKline, Stevenage, UK. Flow cytometry and imaging are two powerful technology platforms that enable high-content analysis of physiologically-relevant cell systems and pre-clinical and clinical biomarkers. Since our first meeting in 2008, we have seen the technology develop and the applications widen across many areas of industrial and academic drug discovery and development. This meeting will focus on translational research in drug discovery and development, big data and analytics, novel and emerging technologies and next generation cytomics in pharmaceutical research.
We aim to bring together the research community working in the field of flow cytometry and imaging with interests in developing and applying the technology for pharmaceutical research. Join scientists from pharma, biotech, CROs and academia to hear talks given by speakers at the cutting edge of cytometry, take part in commercial vendor lab-based workshops, network at the exhibition, innovation forum and speakers dinner and gain strategic insights into solutions for increasing the success of drug discovery and development.
• Translational Flow Cytometry and Imaging in Drug Discovery and Development
New applications and strategies in target identification & validation, cell and gene therapy, immuno-oncology, drug safety, target engagement and dose selection, precision medicine and biopharmaceutical drug development.
• Big Data and Analytics
New Horizons in data management and analytical, statistical and modelling techniques relevant to analysis of high-dimensional and single cell cytometry and imaging data.
• Novel and Emerging Technologies
Next generation instrumentation, and probe and sensor technology for pharmaceutical research.
• Next generation Cytomics in Pharmaceutical Research
Exploration of the latest systems approaches, utilising functional genomic technologies to link the genome and proteome to cellular regulation and function, for predictive medicine.
More information will follow shortly.
Poster presentations at Pharmaceutical Flow Cytometry and Imaging are an excellent opportunity for delegates to network with their colleagues and communicate about their research. To be considered for a poster presentation, you must first submit an abstract for review by the meeting’s Scientific Programme Committee.
For those wishing to participate, a subset of abstracts will also be considered for a short, poster taster session involving a 10 minute oral presentation within the main Symposia sessions. Decisions regarding acceptance of poster abstracts and/or selection for Poster Tasters will be communicated via e-mail in mid-October.
Deadlines for Submission:
Poster Taster Spot: 28th September 2016
General Poster Submission: 4th November 2016
All presenters must be registered as full-conference attendees in order to present at Pharmaceutical Flow Cytometry and Imaging.
Poster size should be no larger than A0 Portrait (W: 841mm x H: 1189mm).
ELRIG organizers will provide supplies to mount your posters, including velcro and/or pushpins.
We apologise that we are unable to accommodate posters which are any larger than A0 Portrait
Posters from Exhibiting Companies:
As an exhibitor, you have one poster spot included with your stand package.
Additional poster spots are £250 +VAT each.
Posters from Non-Exhibiting Companies:
Non-exhibiting vendor companies will be charged £250 +VAT for each poster submitted.
Dr. Beverley Isherwood
Associate Director & Head High Content Biology, Innovative Medicines, AstraZeneca, UK
Bev Isherwood is Associate Director of High Content Biology at AstraZeneca. Bev has global responsibility for phenotypic drug discovery across all therapeutic areas at AstraZeneca. The remit of the High Content Biology group is to deliver high-content phenotypic assays, profiling and a state-of-the-art imaging platform for AstraZeneca globally. Bev’s current research interests include the application of CRISPR, advanced cell models and novel imaging & analytics for target identification, validation and lead optimisation. Bev holds an MA (Natural Sciences) from Cambridge University, a PhD in Molecular Virology from the MRC Virology Unit, Glasgow University and has held positions at both Pfizer in antiviral drug discovery and AstraZeneca in new technologies exploitation.
Principal Scientific Director, Eurofins Pharma Bioanalytical Services
David is a Principal Scientific Director at Eurofins Pharma Bioanalysis, Oxford, UK. He has over 25 years’ experience in the pharmaceutical CRO industry, across a wide range of areas, including roles in cell-based assay modelling, pre-clinical toxicology assessment and clinical trial bioanalysis. During this time he has developed an interest and expertise around immune function assessment and biomarker analysis. His current role in Oxford focuses on the application of flow cytometry and ligand binding techniques as investigative tools in bioanalysis during pharmaceutical drug development. David has been a member of the AAPS Flow Cytometry Action Program Committee since 2014.
Dr Rob Jepras
Dr Rob Jepras has worked in and led several research groups in both industry and public health. He has spent the last 20 years at GSK in the UK working in both Drug Development and Drug Discovery supporting both product development and drug research. Rob currently works in the Drug Discovery and Selection divisons at GSK leading and support drug discovery projects predominantly during the target to candidate phase of drug discovery. A particular focus is to combine high content multi parametric microscopic technologies and human primary cell biology in drug discovery.
Associate Principal Scientist, Global High Content Biology Group
James joined AstraZeneca in 2004 and has worked with applying novel technologies and approaches to Drug Discovery processes across various therapeutic areas. The remit of the High Content Biology Group is to develop and deploy high content phenotypic assays, mechanistic profiling and high content imaging platforms across AstraZeneca. Current research interests include the development and application of array-based CRISPR/Cas9 technologies to aid Target Identification and the use of advanced 2D and 3D cellular models for the prediction of drug safety and efficacy.
Team Leader, Neurology Innovation Centre
Ben Powney is currently a Team leader within the Neurology Innovation Centre at Eisai, UK. He has more than 15 years’ experience as an in vitro pharmacologist within the pharmaceutical industry including positions at Pfizer, Glaxosmithkline and Eisai. During this time he has led preclinical drug discovery projects from inception through to lead optimisation and currently leads a project as part of collaboration between Eisai and University College London. Ben’s current interests include the use of high content imaging and patient derived cell systems to study the roles of dysfunctional subcellular protein trafficking in neurodegeneration.